Lux Med Onkologia Sp. z o.o. — Clinical Trial Site

26 Registered trials

7 Currently recruiting

Organisation

Lux Med Onkologia Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100032883

Address

Ul. Szamocka 6, 01-748, Poland

Departments

LUX MED Onkologia Sp. z o.o. Szpital Szamocka
LuxMed Onkologia Sp. Z.o.o.
N/A
NA
Oddzial Hematoonkologii
Oddzial Onkologii Klinicznej/ Chemioterapii (Clinical Oncology Department/ Chemotherapy )
Oddział Hematoonkologii
Oddział Onkologii Klinicznej/Chemioterapii
Oddział Onkologii Klinicznej i Chemioterapii
Oddział Onkologii Klinicznej i Chemioterapii [email protected]
Oddział Onkologii Klinicznej/Chemioterapii
Oncology
Poradnia Onkologiczna
Szpital Szamocka
Szpital Szamocka Oddział Onkologii Klinicznej/Chemioterapii
Szpital Szamocka, Oddzial onkologii klinicznej/chemioterapii
Szpital Szamocka, Oddział Onkologii Klinicznej/Chemioterapii
Szpital Szamocka; Oddział Onkologii Klinicznej/Chemioterapii

Clinical trials at this site (26)

Search interface

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Metastatic Microsatellite Stable Colorectal Cancer 5
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending

2025-525009-18-00 Pancreatic Ductal Adenocarcinoma 5
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting

2024-517147-31-00 Tumours, Gynecological 9 2025-05-23
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Ly 4 2024-11-14
An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/… Recruiting

2024-513006-61-00 Advanced and/or metastatic solid tumours (colorectal ca 3 2023-08-23
An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OA… Recruiting

2024-510836-31-00 Advanced and/or metastatic solid tumours (colorectal ca 1 2023-02-14
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Newly Diagnosed Advanced Stage Follicular Lymphoma 4 2024-10-10
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Ended

2024-511688-27-00 Myelofibrosis 4 2024-09-19
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Clear cell renal cancer 5 2021-05-11
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended

2023-503421-19-00 Urothelial cancer 5 2020-08-26
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502982-49-00 Metastatic Castration-Resistant Prostate Cancer 4 2024-07-15
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended

2022-501078-20-00 Metastatic Castration-resistant Prostate Cancer 4 2023-05-15
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended

2023-504944-32-00 Non-clear Cell Renal Cell Carcinoma 4 2021-02-17